

IN THE CLAIMS

1-147. (Canceled)

148. (Currently Amended) A method for the treatment of an autoimmune disease in a ~~human or animal~~ subject in need of the treatment, comprising a step of administering an autoimmune disease treatment effective amount of a composition to said subject ~~human or animal~~, wherein the composition comprises

- β -boswellic acid of at least 5% by weight,
- acetyl- β -boswellic acid of at least 5% by weight,
- 11-keto- β -boswellic acid of at least 15% by weight and
- acetyl-11-keto- β -boswellic acid of at least 14% by weight,

wherein said subject is a human or animal.

149. (Previously Presented) The method of claim 148, wherein the composition comprises

β -boswellic acid of at least 12% by weight,
acetyl- β -boswellic acid of at least 5% by weight,
11-keto- β -boswellic acid of at least 15% by weight and
acetyl-11-keto- β -boswellic acid of at least 14% by weight.

150. (Previously Presented) The method of claim 149, wherein the composition comprises

β -boswellic acid of at least 12 to 35% by weight,

acetyl- β -boswellic acid of at least 5 to 35% by weight,
11-keto- β -boswellic acid of at least 15 to 45% by weight and
acetyl-11-keto- β -boswellic acid of at least 14 to 45% by weight.

151. (Previously Presented) The method of claim 148, wherein the autoimmune disease is psoriasis, sarcoidosis, systemic lupus erythematosus, Grave's disease, Hashimoto's thyroiditis, silent thyroiditis, Crohn's disease, Goodpasture syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, myasthenia gravis, Addison's disease, idiopathic hypoparathyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, rheumatoid arthritis or scleroderma.

152-174. (Canceled)

175. (Currently Amended) A method for the treatment of an autoimmune disease in a ~~human or animal~~ subject in need of the treatment, comprising administering an autoimmune disease treatment effective amount of a composition to said subject ~~human or animal~~, wherein the composition comprises acetyl-11-keto- β -boswellic acid, and wherein said subject is a human or animal.

176. (Canceled)

177. (New) The method of claim 148, wherein said subject is a human.

178. (New) The method of claim 175, wherein said subject is a human.

179. (New) A method for the treatment of an autoimmune disease in a subject in need of the treatment, comprising administering an autoimmune disease treatment effective amount of a composition to said subject, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14 to 65% by weight,

acetyl- β -boswellic acid of 5 to 65% by weight,

11-keto- β -boswellic acid of 5 to 60% by weight and

acetyl-11-keto- β -boswellic acid of 5 to 60% by weight,

wherein said subject is a human or animal, and wherein the % by weight is based on the total weight of the composition.

180. (New) The method of claim 179, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14 to 55% by weight,

acetyl- β -boswellic acid of 10 to 55% by weight,

11-keto- β -boswellic acid of 5 to 50% by weight and

acetyl-11-keto- β -boswellic acid of 5 to 50% by weight.

181. (New) The method of claim 180, wherein the composition comprises three boswellic acids selected from the group consisting of

- β -boswellic acid of 14 to 35% by weight,
- acetyl- β -boswellic acid of 10 to 35% by weight,
- 11-keto- β -boswellic acid of 5 to 40% by weight and
- acetyl-11-keto- β -boswellic acid of 5 to 40% by weight.

182. (New) The method of claim 179, wherein the composition comprises three boswellic acids selected from the group consisting of

- β -boswellic acid of 14% by weight,
- acetyl- β -boswellic acid of 5% by weight,
- 11-keto- β -boswellic acid of 5% by weight and
- acetyl-11-keto- β -boswellic acid of 60% by weight.

183. (New) The method of claim 180, wherein the composition comprises three boswellic acids selected from the group consisting of

- β -boswellic acid of 14% by weight,
- acetyl- β -boswellic acid of 10% by weight,
- 11-keto- β -boswellic acid of 5% by weight and
- acetyl-11-keto- β -boswellic acid of 50% by weight.

184. (New) The method of claim 181, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% by weight,
acetyl- β -boswellic acid of 10% by weight,
11-keto- β -boswellic acid of 5% by weight and
acetyl-11-keto- β -boswellic acid of 40% by weight.

185. (New) The method of claim 179, wherein the subject is a human.

186. (New) The method of claim 180, wherein the subject is a human.

187. (New) The method of claim 181, wherein the subject is a human.

188. (New) The method of claim 182, wherein the subject is a human.

189. (New) The method of claim 183, wherein the subject is a human.

190. (New) The method of claim 184, wherein the subject is a human.

191. (New) The method of claim 179, wherein the autoimmune disease is psoriasis, sarcoidosis, systemic lupus erythematosus, Grave's disease, Hashimoto's thyroiditis, silent thyroiditis, Crohn's disease, Goodpasture syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, myasthenia gravis, Addison's disease, idiopathic hypoparathyroidism,

idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, rheumatoid
arthritis or scleroderma.

A handwritten signature in black ink, appearing to be 'C. J. [unclear]', located to the left of the main text block.